<DOC>
	<DOCNO>NCT02863705</DOCNO>
	<brief_summary>The objective study evaluate long-term efficacy safety COMBIGAN速 ( brimonidine tartrate/timolol malate ) patient use COMBIGAN速 ( brimonidine tartrate/timolol malate ) also patient require additional IOP lowering LUMIGAN速 ( bimatoprost ) 0.01 % .</brief_summary>
	<brief_title>Efficacy Safety COMBIGAN速 Korean Patients With Primary Open Angle Glaucoma ( POAG ) Normal Tension Glaucoma ( NTG )</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Low Tension Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients Primary open angle glaucoma ( Regardless Intraocular pressure ) Previous history topical betablocker use insufficiently control IOP Pigmentary exfoliative glaucoma History angleclosure occludable angle gonioscopy Prior filtration laser iridotomy Argon laser trabeculoplasty Selective laser trabeculoplasty perform less 6 month History sign chronic inflammatory eye disease , ocular trauma , potentially progressive retinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>